deltatrials
Completed PHASE3 INTERVENTIONAL 3-arm NCT03308448

Traumatic Optic Neuropathy Treatment Trial 2 (TONTT-2)

Traumatic Optic Neuropathy Treatment Trial 2; Efficacy of Different Doses of Erythropoietin. A Multicenter, Double Blind RCT

Sponsor: Iran University of Medical Sciences

Conditions Traumatic Optic Neuropathy
Interventions Recombinant human erythropoietin
Updated 17 times since 2017 Last updated: Mar 6, 2024 Started: Jan 6, 2018 Primary completion: Aug 6, 2022 Completion: Mar 2, 2023
This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

This PHASE3 trial investigates Traumatic Optic Neuropathy and is currently completed. Iran University of Medical Sciences leads this study, which shows 17 recorded versions since 2018 — indicating substantial longitudinal coverage. The change history captured here reflects the iterative nature of clinical trial conduct.

Status Flow

~Oct 2017 – ~Dec 2017 · 2 months · monthly snapshot~Dec 2017 – ~Jun 2018 · 6 months · monthly snapshot~Jun 2018 – ~Mar 2019 · 9 months · monthly snapshot~Mar 2019 – ~Jan 2020 · 10 months · monthly snapshot~Jan 2020 – ~Jul 2020 · 6 months · monthly snapshot~Jul 2020 – ~Jan 2021 · 6 months · monthly snapshot~Jan 2021 – ~Mar 2021 · 59 days · monthly snapshot~Mar 2021 – ~May 2021 · 2 months · monthly snapshot~May 2021 – ~Feb 2022 · 9 months · monthly snapshot~Feb 2022 – ~Apr 2022 · 59 days · monthly snapshot~Apr 2022 – ~Sep 2022 · 5 months · monthly snapshot~Sep 2022 – ~May 2023 · 8 months · monthly snapshot~May 2023 – ~Apr 2024 · 11 months · monthly snapshot~Apr 2024 – ~Jul 2024 · 3 months · monthly snapshot~Jul 2024 – ~Sep 2024 · 2 months · monthly snapshot~Sep 2024 – ~Sep 2025 · 12 months · monthly snapshot~Sep 2025 – present · 10 months · monthly snapshot

Change History

17 versions recorded

  1. Sep 2025 — Present [monthly]

    Completed PHASE3

  2. Sep 2024 — Sep 2025 [monthly]

    Completed PHASE3

  3. Jul 2024 — Sep 2024 [monthly]

    Completed PHASE3

  4. Apr 2024 — Jul 2024 [monthly]

    Completed PHASE3

  5. May 2023 — Apr 2024 [monthly]

    Completed PHASE3

▶ Show 12 earlier versions

  1. Sep 2022 — May 2023 [monthly]

    Completed PHASE3

    Status: Recruiting → Completed

  2. Apr 2022 — Sep 2022 [monthly]

    Recruiting PHASE3

  3. Feb 2022 — Apr 2022 [monthly]

    Recruiting PHASE3

  4. May 2021 — Feb 2022 [monthly]

    Recruiting PHASE3

  5. Mar 2021 — May 2021 [monthly]

    Recruiting PHASE3

  6. Jan 2021 — Mar 2021 [monthly]

    Recruiting PHASE3

  7. Jul 2020 — Jan 2021 [monthly]

    Recruiting PHASE3

  8. Jan 2020 — Jul 2020 [monthly]

    Recruiting PHASE3

  9. Mar 2019 — Jan 2020 [monthly]

    Recruiting PHASE3

  10. Jun 2018 — Mar 2019 [monthly]

    Recruiting PHASE3

  11. Dec 2017 — Jun 2018 [monthly]

    Recruiting PHASE3

    Status: Not Yet Recruiting → Recruiting

  12. Oct 2017 — Dec 2017 [monthly]

    Not Yet Recruiting PHASE3

    First recorded

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:
  • Iran University of Medical Sciences
  • Mashhad University of Medical Sciences
  • Tehran University of Medical Sciences
Data source: Iran University of Medical Sciences

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations